A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma
- Determine the effectiveness and toxic effects of intensive salvage therapy and
radiotherapy in previously irradiated patients with recurrent head and neck cancer.
- Determine the feasibility and effectiveness of amifostine at limiting or minimizing
side effects of repeat irradiation in these patients.
OUTLINE: Patients undergo surgical resection of gross disease (if not already done) followed
by 4-6 weeks of rest. Patients receive radiotherapy over 5 consecutive days on weeks 1, 2,
4, and 5. Intravenous cisplatin is administered on days 1-3 and 29-31. Intravenous
amifostine is administered 15-30 minutes prior to radiotherapy and cisplatin therapy.
Patients receive fluorouracil IV continuously on days 1-4 and 29-32.
Patients are followed every month for 1 year, every 2 months for 1 year, every 3 months for
1 year, every 4 months for 1 year, then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Primary Purpose: Treatment
Mitchell Machtay, MD
Abramson Cancer Center of the University of Pennsylvania
United States: Federal Government
|University of Pennsylvania Cancer Center||Philadelphia, Pennsylvania 19104|